New hope is emerging for patients battling treatment-resistant cancers and debilitating blood disorders. Cetya Therapeutics, a Fort Collins-based pharmaceutical company, is developing treatments that could significantly extend lives and improve quality of life for those facing some of the toughest medical conditions. What’s more, they are redefining how these treatments are made.
With the recent issuance of a patent for their novel manufacturing process, Cetya is ensuring that its innovative drugs can reach more patients in need, faster and more cost-effectively.
A Better Way to Make Life-Saving Treatments
One of the biggest challenges in drug development isn’t just discovering new treatments—it’s manufacturing them safely and at scale. Cetya’s recently issued patent (U.S. Patent No. 12,227,522) protects a new process for manufacturing CT-101, its lead HDAC inhibitor, along with other key drugs in its portfolio, such as CT-102 and CT-108.
The new process eliminates the need for high-potency equipment, making production safer for workers and reducing costs for large-scale manufacturing. Previously, the synthetic process involved a bioactive intermediate that required high-containment equipment to protect those handling it. Cetya’s improved method revises that and incorporates an inactive intermediate, making the process safer and more efficient.
Strengthening the Future of Cancer and Blood Disorder Treatments
Originally developed for cancer treatment, CT-101 is proving to be more versatile than expected. As an HDAC inhibitor, it has shown promise not only in fighting tumors but also in treating sickle cell disease and chronic inflammatory conditions. HDAC inhibitors work by modifying the way genes are expressed, which can have significant effects on cancer cell growth and blood cell production.
For cancer patients, CT-101’s mechanism of action offers a novel approach to tackling treatment-resistant tumors. HDAC inhibitors have the potential to reprogram cancer cells, making them more responsive to other therapies or even triggering their destruction. By improving the manufacturing process, Cetya is making it easier to produce CT-101 at the scale needed for widespread clinical trials and, eventually, patient treatment. The ability to produce CT-101 and its related compounds more efficiently means that patients suffering from these conditions may have greater access to groundbreaking therapies.
“This patent exemplifies Cetya’s position as a leader in novel HDAC inhibitor chemistry, radically altering the manufacturing process to improve the safety of production personnel and reduce the capital needs for scale-up and manufacture of clinical-grade material,” said John Adair, CEO of Cetya.
With this patent in place, Cetya is better positioned to accelerate clinical development and secure partnerships to advance their research. The company’s focus on both innovation and safety ensures that its treatments will not only be effective but also produced in a way that minimizes risks for everyone involved in the manufacturing process.
For more information on Cetya’s work and future developments, visit cetyatherapeutics.com.
This story is part of CSU STRATA’s Securing Innovation series. The series explores how patents, copyrights, and trademarks drive progress by highlighting stories of innovators throughout the CSU System. Check out our blog for future stories like this.